Corrigendum to “Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: A randomized, double-blind, placebo-controlled trial” [Schizophr. Res. 176 (2016) 264–271] (S0920996416303127) (10.1016/j.schres.2016.06.030));Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: A randomized, double-blind, placebo-controlled trial

Schizophrenia Research

Volumn 176, Issue 2-3, 2016, Pages 264-271

  Durgam, Suresh ^a   Earley, Willie ^a   Li, Rui ^a   Li, Dayong ^a   Lu, Kaifeng ^a   Laszlovszky, István ^b   Fleischhacker, W Wolfgang ^c   Nasrallah, Henry A ^d  

^a ALLERGAN INC   (United States)

^b GEDEON RICHTER LTD   (Hungary)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^d SAINT LOUIS UNIVERSITY   (United States)

Author keywords

Cariprazine; Long term treatment; Oral antipsychotics; Randomized controlled trial; Relapse prevention; Schizophrenia

Indexed keywords

CARIPRAZINE; CREATINE KINASE; PLACEBO; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE;

ADULT; AGGRESSION; AKATHISIA; ANXIETY; ARTICLE; BACKACHE; CONSTIPATION; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; EXTRAPYRAMIDAL SYNDROME; FEMALE; HEADACHE; HOSPITALIZATION; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; RELAPSE; RESTLESSNESS; RHINOPHARYNGITIS; SCHIZOPHRENIA; SUICIDE; TREMOR; VIOLENCE; WEIGHT GAIN; ADOLESCENT; CLINICAL TRIAL; FOLLOW UP; INTERNATIONAL COOPERATION; MIDDLE AGED; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PSYCHOLOGICAL RATING SCALE; SECONDARY PREVENTION; YOUNG ADULT;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERNATIONALITY; MALE; MIDDLE AGED; PIPERAZINES; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SECONDARY PREVENTION; YOUNG ADULT;

EID: 84978821878     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2017.04.020     Document Type: Erratum

References (36)

1. American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders. fourth ed., 2000, American Psychiatric Association, Washington, DC (Text Revision).
2. Arato, M., O'Connor, R., Meltzer, H.Y., Group, Z.S., A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study. Int. Clin. Psychopharmacol. 17:5 (2002), 207–215.
3. Axelrod, B.N., Goldman, R.S., Alphs, L.D., Validation of the 16-item Negative Symptom Assessment. J. Psychiatr. Res. 27:3 (1993), 253–258.
4. Barnes, T.R., A rating scale for drug-induced akathisia. Br. J. Psychiatry 154 (1989), 672–676.
5. Beasley, C.M. Jr., Sutton, V.K., Hamilton, S.H., Walker, D.J., Dossenbach, M., Taylor, C.C., Alaka, K.J., Bykowski, D., Tollefson, G.D., Olanzapine Relapse Prevention Study, G., A double-blind, randomized, placebo-controlled trial of olanzapine in the prevention of psychotic relapse. J. Clin. Psychopharmacol. 23:6 (2003), 582–594.
6. Durgam, S., Starace, A., Li, D., Migliore, R., Ruth, A., Németh, G., Laszlovszky, I., An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: a phase II, randomized clinical trial. Schizophr. Res. 152:2–3 (2014), 450–457.
7. Durgam, S., Cutler, A.J., Lu, K., Migliore, R., Ruth, A., Laszlovszky, I., Németh, G., Meltzer, H.Y., Cariprazine in acute exacerbation of schizophrenia: a fixed-dose, phase III randomized, double-blind, placebo- and active-controlled trial. J. Clin. Psychiatry 76:12 (2015), e1574–e1582.
8. Emsley, R., Chiliza, B., Asmal, L., Harvey, B.H., The nature of relapse in schizophrenia. BMC Psychiatry, 13, 2013, 50.
9. Fleischhacker, W.W., Arango, C., Arteel, P., Barnes, T.R., Carpenter, W., Duckworth, K., Galderisi, S., Halpern, L., Knapp, M., Marder, S.R., Moller, M., Sartorius, N., Woodruff, P., Schizophrenia—time to commit to policy change. Schizophr. Bull. 40:Suppl. 3 (2014), S165–S194.
10. Graff-Guerrero, A., Mamo, D., Shammi, C.M., Mizrahi, R., Marcon, H., Barsoum, P., Rusjan, P., Houle, S., Wilson, A.A., Kapur, S., The effect of antipsychotics on the high-affinity state of D2 and D3 receptors: a positron emission tomography study With [11C]-(+)-PHNO. Arch. Gen. Psychiatry 66:6 (2009), 606–615.
11. Guy, W., The Abnormal Movement Scale. ECDEU Assessment Manual for Psychopharmacology. 1976, National Institute of Mental Health, Rockville, MD, 218–222 (DHEW Publication No. 76-338).
12. Guy, W., ECDEU Assessment Manual for Psychopharmacology. Revised. DHEW publication, no. (ADM) 76-338. 1976, US Dept of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs, Rockville, MD (1976. p. 218-22, 534-7).
13. Gyertyán, I., Sághy, K., Laszy, J., Elekes, O., Kedves, R., Gémesi, L.I., Pásztor, G., Zájer-Balázs, M., Kapás, M., Csongor, E.Á., Domány, G., Kiss, B., Szombathelyi, Z., Subnanomolar dopamine D3 receptor antagonism coupled to moderate D2 affinity results in favourable antipsychotic-like activity in rodent models: II. Behavioural characterisation of RG-15. Naunyn Schmiedeberg's Arch. Pharmacol. 378:5 (2008), 529–539.
14. Gyertyán, I., Kiss, B., Sághy, K., Laszy, J., Szabó, G., Szabados, T., Gemesi, L.I., Pásztor, G., Zájer-Balázs, M., Kapás, M., Csongor, E.Á., Domány, G., Tihanyi, K., Szombathelyi, Z., Cariprazine (RGH-188), a potent D3/D2 dopamine receptor partial agonist, binds to dopamine D3 receptors in vivo and shows antipsychotic-like and procognitive effects in rodents. Neurochem. Int. 59:6 (2011), 925–935.
15. Kane, J.M., Treatment strategies to prevent relapse and encourage remission. J. Clin. Psychiatry 68:Suppl. 14 (2007), 27–30.
16. Kane, J.M., Mackle, M., Snow-Adami, L., Zhao, J., Szegedi, A., Panagides, J., A randomized placebo-controlled trial of asenapine for the prevention of relapse of schizophrenia after long-term treatment. J. Clin. Psychiatry 72:3 (2011), 349–355.
17. Kane, J.M., Zukin, S., Wang, Y., Lu, K., Ruth, A., Nagy, K., Laszlovszky, I., Durgam, S., Efficacy and safety of cariprazine in acute exacerbation of schizophrenia: results from an international, phase III clinical trial. J. Clin. Psychopharmacol. 35:4 (2015), 1–7.
18. Kay, S.R., Fiszbein, A., Opler, L.A., The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 13:2 (1987), 261–276.
19. Kiss, B., Laszlovszky, I., Horváth, A., Némethy, Z., Schmidt, E., Bugovics, G., Fazekas, K., Gyertyán, I., Csongor, E.Á., Domány, G., Szombathelyi, Z., Subnanomolar dopamine D3 receptor antagonism coupled to moderate D2 affinity results in favourable antipsychotic-like activity in rodent models: I. Neurochemical characterisation of RG-15. Naunyn Schmiedeberg's Arch. Pharmacol. 378:5 (2008), 515–528.
20. Kiss, B., Horváth, A., Némethy, Z., Schmidt, E., Laszlovszky, I., Bugovics, G., Fazekas, K., Hornok, K., Orosz, S., Gyertyán, I., Csongor, E.Á., Domány, G., Tihanyi, K., Adham, N., Szombathelyi, Z., Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile. J. Pharmacol. Exp. Ther. 333:1 (2010), 328–340.
21. Laszy, J., Laszlovszky, I., Gyertyán, I., Dopamine D3 receptor antagonists improve the learning performance in memory-impaired rats. Psychopharmacology 179:3 (2005), 567–575.
22. Lehman, A.F., Lieberman, J.A., Dixon, L.B., McGlashan, T.H., Miller, A.L., Perkins, D.O., Kreyenbuhl, J., American Psychiatric, A., Steering Committee on Practice, G., Practice guideline for the treatment of patients with schizophrenia, second edition. Am. J. Psychiatry 161:2 Suppl. (2004), 1–56.
23. Leucht, S., Heres, S., Epidemiology, clinical consequences, and psychosocial treatment of nonadherence in schizophrenia. J. Clin. Psychiatry 67:Suppl. 5 (2006), 3–8.
24. Leucht, S., Tardy, M., Komossa, K., Heres, S., Kissling, W., Salanti, G., Davis, J.M., Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet 379:9831 (2012), 2063–2071.
25. Mizrahi, R., Agid, O., Borlido, C., Suridjan, I., Rusjan, P., Houle, S., Remington, G., Wilson, A.A., Kapur, S., Effects of antipsychotics on D3 receptors: a clinical PET study in first episode antipsychotic naive patients with schizophrenia using [11C]-(+)-PHNO. Schizophr. Res. 131:1–3 (2011), 63–68.
26. Morken, G., Widen, J.H., Grawe, R.W., Non-adherence to antipsychotic medication, relapse and rehospitalisation in recent-onset schizophrenia. BMC Psychiatry, 8, 2008, 32.
27. Morosini, P.L., Magliano, L., Brambilla, L., Ugolini, S., Pioli, R., Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. Acta Psychiatr. Scand. 101:4 (2000), 323–329.
28. Nakamura, T., Kubota, T., Iwakaji, A., Imada, M., Kapás, M., Morio, Y., Clinical pharmacology study of cariprazine (MP-214) in patients with schizophrenia (12-week treatment). Drug Des. Dev. Ther. 10 (2016), 327–338.
29. Olivares, J.M., Sermon, J., Hemels, M., Schreiner, A., Definitions and drivers of relapse in patients with schizophrenia: a systematic literature review. Ann. General Psychiatry, 12(1), 2013, 32.
30. Pigott, T.A., Carson, W.H., Saha, A.R., Torbeyns, A.F., Stock, E.G., Ingenito, G.G., Aripiprazole Study, G., Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. J. Clin. Psychiatry 64:9 (2003), 1048–1056.
31. Posner, K., Brown, G.K., Stanley, B., Brent, D.A., Yershova, K.V., Oquendo, M.A., Currier, G.W., Melvin, G.A., Greenhill, L., Shen, S., Mann, J.J., The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am. J. Psychiatry 168:12 (2011), 1266–1277.
32. Schwartz, J.C., Diaz, J., Pilon, C., Sokoloff, P., Possible implications of the dopamine D(3) receptor in schizophrenia and in antipsychotic drug actions. Brain Res. Brain Res. Rev. 31:2–3 (2000), 277–287.
33. Simpson, G.M., Angus, J.W., A rating scale for extrapyramidal side effects. Acta Psychiatr. Scand .Suppl. 212 (1970), 11–19.
34. Taylor, D., Psychopharmacology and adverse effects of antipsychotic long-acting injections: a review. Br. J. Psychiatry Suppl. 52 (2009), S13–S19.
35. Taylor, M., Chaudhry, I., Cross, M., McDonald, E., Miller, P., Pilowsky, L., Strickland, P., Relapse Prevention in Schizophrenia Consensus, G., Towards consensus in the long-term management of relapse prevention in schizophrenia. Hum. Psychopharmacol. 20:3 (2005), 175–181.
36. Whiteford, H.A., Degenhardt, L., Rehm, J., Baxter, A.J., Ferrari, A.J., Erskine, H.E., Charlson, F.J., Norman, R.E., Flaxman, A.D., Johns, N., Burstein, R., Murray, C.J., Vos, T., Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. Lancet 382:9904 (2013), 1575–1586.